Notícias

Pinterest keeps sliding lower while its closest peers barely flinch, and no news has surfaced to explain the gap. Something is moving inside Pinterest's shareholder base, and the pattern is getting harder to ignore.

(Updates with latest market prices and developments.) US benchmark equity indexes were mixed intr

Financial stocks were lower in Tuesday afternoon trading, with the NYSE Financial Index falling 1.5%

Key TakeawaysNebius’s reported EBITDA margin swung from negative 24. 33% in Q4 2025 to 21.

Public investors will now test AI drug-discovery enthusiasm

When management takes the stage in New York, demand from an unexpected source could change how Wall Street prices the stock.

One key rate move sits behind the bullish forecast

Spotify's Q2 gross margin rose to 33.4% as Premium growth outpaced music costs and Ad-Supported gains lifted operating profitability.

Investor expectations have become concentrated at unprecedented scale

A policy shift could finally move quantum beyond research

The 1,156 transactions in July totaled between roughly $79 million and $270 million, according to a CNBC analysis

Tight supply could keep pricing power stronger for longer

Over the last six months, S&P Global’s shares have sunk to $405.30, producing a disappointing 5.5% loss - a stark contrast to the S&P 500’s 16.2% gain. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.

In an interview with CNBC, Ives said Meta’s roughly 3.5 billion users across its platforms give it a significant existing audience for consumer AI products.

Circle sells Binance $100M in discounted CRCL shares as the pair expand their USDC deal.

Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 to about $173. The S&P 500 gained 18.5% with dividends reinvested over the same window, and Pfizer (PFE) about 23%. The run's central event came on August 19, 2026, when Merck and Moderna said a Phase III trial of their cancer vaccine, intismeran autogene, met its endpoints in melanoma. A rough timetable for the trial was public long before the stock moved, but its result was not.

Should investors bet more on the AI infrastructure bottlenecks than on other tech trends, such as social media? Today's Market Hang panel consists of Host Turney Duff, Yahoo Finance Executive Editor Brian Sozzi, Defiance ETFs CIO Sylvia Jablonski, Interactive Brokers chief strategist Steve Sosnick, and Gerber Kawasaki Wealth & Investment Management CEO Ross Gerber.

Tech stocks advanced Tuesday afternoon, with the State Street Technology Select Sector SPDR ETF (XLK

Consumer stocks advanced Tuesday afternoon, with the State Street Consumer Staples Select Sector SPD

Both Paramount and Warner Bros. jumped on Monday after settling an antitrust lawsuit that could have blocked the merger.

Binance takes a $100 million equity stake in Circle and signs a five-year deal to promote USDC on its exchange.

Lee said the Fed’s September rate hike left stocks oversold, setting the stage for a potential rebound.

U.S. card issuers saw August delinquencies and charge-offs rise sequentially, though both remained below year-ago levels. What does this mean for credit quality?

Rigetti is tackling a coherence-time bottleneck in its 108-qubit Cepheus system to improve gate fidelity and quantum reliability.

Earning $211,000 a year might make a $600,000 house sound manageable. For one 40-year-old, the thought of taking on that kind of expense is making him question whether buying a home makes sense at all. His wife wants to leave...

Beverage giant Coca-Cola Co has been a staple to the investment portfolio of Berkshire Hathaway for years. With Warren Buffett stepping down as chairman of the conglomerate, here’s a look back at how much the value of the beverage giant...

Salesforce's agentic AI business is scaling at a pace that would make most enterprise software companies envious, yet the stock keeps getting priced like a relic from the CRM era. Something in that gap looks like an opportunity Wall Street has not yet caught up to.

INOD is expanding into agentic reinforcement learning, winning AI programs and scaling enterprise tools as revenues surge and competition intensifies.

iRhythm's Q2 momentum, AI-driven predictive care and deeper EHR integration support growth, though reimbursement pressures remain.

Root extends its exclusive Carvana insurance deal through at least August 2028, strengthening embedded distribution as Direct competition intensifies.